Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference
Vaxcyte (Nasdaq: PCVX) said management will take part in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026 at 2:15 p.m. ET / 11:15 a.m. PT.
Rhea-AI Summary
Vaxcyte (Nasdaq: PCVX) said management will take part in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026 at 2:15 p.m. ET / 11:15 a.m. PT. A live webcast will be available on the company investor site, with a replay for ~30 days.
Positive
- None.
Negative
- None.
Details
News Market Reaction – PCVX
In the Apr 8 session, PCVX declined 0.97%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Conference date
- April 14, 2026
- 25th Annual Needham Virtual Healthcare Conference
- Presentation time (ET)
- 2:15 p.m. ET
- Fireside chat session
- Presentation time (PT)
- 11:15 a.m. PT
- Fireside chat session
- Webcast replay period
- 30 days
- Replay availability after conference
Historical Context
-
Completed enrollment of OPUS-1 and OPUS-2 Phase 3 VAX-31 adult trials.
-
Published positive VAX-31 Phase 1/2 adult data in The Lancet Infectious Diseases.
-
Reported FY 2025 results, strong cash of ~$2.44B and $632.5M public offering.
-
Dosed first participants in OPUS-3 Phase 3 trial for VAX-31 in adults.
-
Announced timing of Q4 and full-year 2025 results and business update call.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN CARLOS, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2026 at 2:15 p.m. ET / 11:15 a.m. PT.
A live webcast of the fireside chat can be accessed through the Investors & Media section of the Company’s website at http://investors.vaxcyte.com. A replay of the webcast will be available for approximately 30 days following the conference.
About Vaxcyte
Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate being evaluated in the OPUS Phase 3 adult clinical program and in a Phase 2 infant clinical program, is being developed for the prevention of invasive pneumococcal disease (IPD) and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, a 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market. VAX-31 and VAX-24 are designed to improve upon standard-of-care PCVs by covering the serotypes in circulation that cause a significant portion of IPD and are associated with high case-fatality rates, antibiotic resistance and meningitis, while maintaining coverage of previously circulating strains. VAX-XL, in earlier-stage development, also leverages the Company’s carrier-sparing, site-specific conjugation technology with the aim of further expanding coverage to deliver the broadest-spectrum candidate in the Company’s PCV franchise.
Vaxcyte is re-engineering the way highly complex vaccines are made through XpressCF®, its cell-free protein synthesis platform exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company’s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to develop high-fidelity vaccines with enhanced immunological benefits. Vaxcyte’s pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections, and VAX-GI, a vaccine candidate designed to prevent Shigella. For more information, visit www.vaxcyte.com.
Contact:
Jeff Macdonald, Executive Director, Investor Relations
Vaxcyte, Inc.
917-371-0940
investors@vaxcyte.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.